UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): **October 30, 2015**

SIENTRA, INC.

(Exact Name of Registrant as Specified in Its Charter)

Delaware	**001-36709**	**20-5551000**
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

420 South Fairview Avenue, Suite 200
Santa Barbara, CA 93117
(Address of Principal Executive Offices and Zip Code)

(805) 562-3500
(Registrant's Telephone Number, Including Area Code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01. Other Events.

On October 30, 2015, Sientra, Inc. (the " ***Company*** " or " ***Sientra*** ") sent a letter to surgeons regarding the recent fire at Silimed's manufacturing facilities and other business updates, including the status of the Company's review of products manufactured by Silimed and testing of the Company's existing inventory. A copy of the letter is filed as Exhibit 99.1 and is incorporated herein by reference.

Forward-Looking Statements

Certain statements incorporated by reference into this Current Report on Form 8-K are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, relating to, among other things, the future performance of Sientra that are based on management's current assumptions and expectations of future events and involve risks and uncertainties. Forward-looking statements include, but are not limited to, statements regarding: the results and timing of Sientra's independent review of products manufactured by Silimed; Sientra's current inventory supply; and the actions that the FDA may take in response to such matters and as a result of Sientra's independent review. Such statements are subject to risks and uncertainties. The Company's business, strategy, operations or financial performance, and actual results may differ materially from those predicted or implied. All statements other than statements of historical fact are forward-looking statements. The words ''believe,'' ''will,'' ''continue,'' ''expect,'' ''plan,'' or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes are intended to identify estimates, projections and other forward-looking statements. More information about factors that could cause actual results to differ materially from those incorporated by reference into this Current Report on Form 8-K can be found under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's most recent Quarterly Report on Form 10-Q at http://investors.sientra.com/financial-info/sec-filings/default.aspx or the SEC's website at www.sec.gov. Undue reliance should not be placed on the forward-looking statements incorporated by reference herein, which are based on information available to the Company on the date hereof, and except to the extent required by law, Sientra assumes no obligation to update such statements.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
99.1	Letter of Sientra, Inc. dated October 30, 2015.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereto duly authorized.

SIENTRA, INC.

Dated: October 30, 2015

By: /s/ Hani Zeini
Hani Zeini
President and Chief Executive Officer

INDEX TO EXHIBITS

Exhibit No.	Description
99.1	Letter of Sientra, Inc. dated October 30, 2015.

Exhibit 99.1

sientra.

SIMPLICITY IS BEAUTY™

October 30, 2015

Dear Valued Plastic Surgeon,

As I have committed previously, I am sending you this update to keep you informed and provide additional details as they are available to us.

As you already know by now, there was a fire at one of the two buildings at Silimed's facility in Brazil. Based on our preliminary discussions with Silimed, we learned that the fire occurred in the building where Sientra's breast implants are primarily manufactured. Silimed has indicated that a smaller production facility in Silimed's second building, which was not impacted by the fire, has the potential to be modified for breast implant manufacturing. In order to begin the manufacturing of breast implants in this second building, certain areas in this facility would need to be reconfigured and receive certification and approval by appropriate regulatory bodies. We are currently working with Silimed to assess the feasibility and timing of such a plan.

In regards to our own review that I previously communicated, we are continuing it in earnest with the assistance of independent experts in quality management systems, Good Manufacturing Practices (GMP) and data-based risk assessment. Our review covers among other items:

- Documentation related to the matter in question;
- Procedures for manufacturing Sientra's products;
- Environmental monitoring;
- Data, testing and analysis conducted by or on behalf of Silimed; and
- Potential corrective actions implemented by Silimed to resolve the regulatory issues and reinstate Silimed's ability to manufacture products.

We have also initiated testing of products in our existing finished goods inventory. Our expectation is that results of the tests along with our ongoing review will allow us to identify the steps required to provide you with our products, following consultation with and concurrence from the FDA. As you would expect, we have been in continuous communication with the FDA but we cannot and will not speculate on the timing or outcome of FDA's decision. Rest assured, we have been working tirelessly to complete this review and expect to be in a position to present our findings to the FDA by the end of calendar year 2015. Based on historical demand patterns and evaluation, we believe that our current inventory supply is approximately 12 months.

Let me emphasize that no reports of adverse events and no risks to patient health have been identified related to this matter. This finding has been reiterated by the foreign regulators reviewing this matter in their public announcements. Y ou can continue to reassure your patients as needed by informing them that there has been no indication that these issues would pose a threat to their safety. Consistent with standard patient follow up, you should continue to advise your patients who have received Sientra implants to contact you if they experience any complications.

It is important to note that we are also focused on evaluating all options going forward to ensure that we can continue to provide you and your patients with our high-quality, differentiated products.

We continue to be well funded with a cash and cash equivalents balance of $148.9 million as of September 30, 2015. Earlier this week we paid in full our term loans totaling $24.5 million, and as a result the company has no outstanding debt obligations.

I want to end this communication with heartfelt gratitude to all of our surgeons who I personally met with last week during ASPS in Boston and who I have been communicating with regularly. Thank you for your continued support and words of encouragement during these challenging times. Our commitment to board-certified plastic surgeons is unwavering and we promise to double and triple our efforts to earn the privilege of your business as soon as we resolve this matter and are back in a position to offer you our differentiated value proposition and the unparalleled level of service, clinical transparency and evidence-based promotion you expect from us.

Thank you for the understanding and patience throughout this process which are deeply appreciated by everyone in our Sientra community.

Respectfully,

Hani Zeini
Founder and Chief Executive Officer
Sientra, Inc.